The drug-funding agency estimated that 1200 patients would benefit this year, rising to more than 5000 annually after 2030.

Pharmac currently funds venetoclax for a different type of blood cancer called chronic lymphocytic leukaemia, and funds upadacitinib for some people with rheumatoid arthritis. Azacitidine is currently ...

The overall response rate (ORR) in all evaluable patients was 46% in all Cohort 3 patients and 67% in AML-MRC patients, far exceeding the targeted ORR of 20%. In the subgroup of patients with ...

During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax and azacitidine for ...